Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
meningioma
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "meningioma" in MCE Product Catalog:
Cat. No.: HY-400902
CAS No.: 2506273-81-8
Target:
Research Areas:
VT3989 is an orally active pan-TEAD autopalmitoylation inhibitor that modulates the Hippo signaling pathway. VT3989 directly binds to TEAD transcription factors to block their palmitoylation modification, thereby disrupting the formation of YAP/TAZ-TEAD complexes and inhibiting downstream oncogenic transcriptional activity. VT3989 effectively inhibits the growth of NF2-deficient schwannoma and meningioma cells and reverses the Schwann cell phenotype. In addition, VT3989 exerts a synergistic effect when combined with Osimtinib (HY-15772) in EGFR-mutant non-small cell lung cancer models, significantly delaying tumor recurrence and prolonging survival. VT3989 can be used for the research of epithelioid hemangioendothelioma, malignant pleural mesothelioma, type 2 neurofibromatosis and related advanced solid tumors .
Cat. No.: HY-B1016
CAS No.: 15421-84-8
Synonyms: AR-12008
Research Areas:
Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury .
Cat. No.: HY-P990643
Target:
Research Areas:
OS-2966 is a humanized neutralizing monoclonal antibody (huIgG1κ) targeting human CD29 (β1 integrin/ITGB1). OS-2966 blocks integrin β1 signaling, inhibits tumor cell proliferation, invasion, migration and mesenchymal phenotype, and enhances the efficacy of oncolytic herpes simplex virus-1 (oHSV) and anti-angiogenic therapies. OS-2966 can be used in research related to triple-negative breast cancer, high-grade meningioma, glioblastoma and ovarian cancer .
Cat. No.: HY-B1016R
CAS No.: 15421-84-8
Synonyms: AR-12008 (Standard)
Research Areas:
Trapidil (Standard) (AR-12008 (Standard)) is the analytical standard of Trapidil (HY-B1016R). This product is intended for research and analytical applications. Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury.
Cat. No.: HY-E70559
CAS No.: 65802-85-9
Target:
Research Areas:
Prostaglandin D synthase is a biomarker for meningioma cells and coronary artery disease. Lipocalin-type Prostaglandin D synthase (L-PGDS) is present in the atherosclerotic plaque of the human coronary artery and can be detectable in human serum .
Cat. No.: HY-183124
CAS No.: 2982897-45-8
AKT1-IN-12 is a AKT1 inhibitor. AKT1-IN-12 is applicable to research related to breast cancer, colorectal cancer and meningioma .
Cat. No.: HY-400902R
CAS No.: 2506273-81-8
Target:
Research Areas:
VT3989 (Standard) is the analytical standard of VT3989 (HY-400902). This product is intended for research and analytical applications. VT3989 is an orally active pan-TEAD autopalmitoylation inhibitor that modulates the Hippo signaling pathway. VT3989 directly binds to TEAD transcription factors to block their palmitoylation modification, thereby disrupting the formation of YAP/TAZ-TEAD complexes and inhibiting downstream oncogenic transcriptional activity. VT3989 effectively inhibits the growth of NF2-deficient schwannoma and meningioma cells and reverses the Schwann cell phenotype. In addition, VT3989 exerts a synergistic effect when combined with Osimtinib (HY-15772) in EGFR-mutant non-small cell lung cancer models, significantly delaying tumor recurrence and prolonging survival. VT3989 can be used for the research of epithelioid hemangioendothelioma, malignant pleural mesothelioma, type 2 neurofibromatosis and related advanced solid tumors .
Cat. No.: HY-180306
CAS No.: 84693-92-5
Research Areas:
Fluoroestradiol is an Estrogen receptor PET imaging tracer precursor. Fluoroestradiol, when radiolabeled with 18F, can be used as an Estrogen receptor PET imaging tracer. 18F-Fluoroestradiol exhibits the highest uptake selectivity and target-to-background ratio among
several 18F-labeled estrogens. 18F-Fluoroestradiol has demonstrated Estrogen receptor expression in normal brain tissues and in meningiomas. 18F-Fluoroestradiol can quantify regional Estrogen receptor expression in breast cancer. 18F-Fluoroestradiol has potential applications in assessing and monitoring heterogeneity in ovarian cancer .
several 18F-labeled estrogens. 18F-Fluoroestradiol has demonstrated Estrogen receptor expression in normal brain tissues and in meningiomas. 18F-Fluoroestradiol can quantify regional Estrogen receptor expression in breast cancer. 18F-Fluoroestradiol has potential applications in assessing and monitoring heterogeneity in ovarian cancer .
Cat. No.: HY-119080
CAS No.: 532435-68-0
Target:
Research Areas:
CP8754 is an orally active, selective human progesterone receptor (hPR) antagonist that blocks progesterone-mediated signaling pathways. CP8754 competitively inhibits the binding of [ 3H]-progesterone to hPR. And in vitro, CP8754 inhibits progesterone-dependent exogenous luciferase and endogenous alkaline phosphatase expression; while in vivo, CP8754 inhibits rabbit endometrial transformation. CP8754 does not significantly bind to human glucocorticoid receptors (hGR), estrogen receptors (hER), or rat androgen receptors (rAR). CP8754 can be used in the study of progesterone-related diseases such as breast cancer, endometriosis, uterine fibroids, and meningioma, as well as hormone-dependent tumors .
Cat. No.: HY-138032
CAS No.: 326914-17-4
Synonyms: N,N-Dimethyl sunitinib
Research Areas:
SU11657 (N,N-Dimethyl sunitinib) is an orally active multi-targeted tyrosine kinase inhibitor with IC50 values of 0.04 μM (c-Kit), 0.005 μM (PDGFR), 0.013 μM (VEGFR1), 0.017 μM (VEGFR2) and 50 nM (FLT3), respectively. SU11657 exhibits anti-angiogenic activity. SU11657 delays leukemia progression, synergizes with ATRA (HY-14649) to reduce leukemia burden, and inhibits symptoms and tissue damage associated with rheumatoid arthritis. SU11657 can be used in research related to FLT3-mutated acute promyelocytic leukemia, rheumatoid arthritis, neuroblastoma, and benign/atypical meningioma .
Cat. No.: HY-P703317
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TMEM97; Sigma Intracellular Receptor 2; Transmembrane Protein 97; Sigma-2 Receptor; MAC30; TMEM97 Protein; Sigma2 Receptor; Sigma2R; S2R; Σ2R; meningioma-Associated Protein 30
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-L188
2,134 compounds
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.
MCE designs a unique collection of 2,134 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
